Importance of patient's choice in the treatment of erectile dysfunction

Erectile dysfunction (ED) affects nearly one out of two men over age 45. ED is known to alter the quality of life of patients, and to affect significantly their sexual life and relations, as well as those of their female partners. Phosphodiesterase 5 inhibitors (PDE5) inhibitors currently represent the reference treatment for ED, because of their efficacy and good tolerability. The presence of erectile disorders capable of altering considerably the life of a couple makes it necessary to find ways for patients and their partners to get more involved in the treatment choices. A "customized" solution responding to patient's needs and resulting from a decision shared with the patient and his partner will allow a better compliance and efficacy of the treatment.